Samsung v ZTE: Will multiple rate setting trials become more common?

​
November 12, 2026

As has been widely reported, it appears as if Samsung and ZTE may have settled their 5G licensing dispute. Although not the first case in which parallel rate setting actions have been brought (for example Conversant’s dispute with Huawei and ZTE entailed rate setting proceedings in both the UK and China, alongside German infringement claims), this is the first time multiple rate setting judgments have been produced by different courts in the same dispute. As well as the rate setting judgments from the UK and China, it is also notable that the Munich court also set out a hypothetical rate setting. This gives rise to the question as to whether this will develop into a trend, and will multiple rate setting actions become more common in FRAND disputes?

Which courts are willing to set FRAND rates?

To date, few courts have been willing to determine a FRAND rate, especially on a global basis. The UK courts have done so over the last ten years, starting with the case of Unwired Planet v Huawei. The Chinese courts have also been willing to do so, with several parties requesting rate determination on either a global basis or in respect of China only.  In contrast, the US courts will only do so where both parties consent to a rate setting, which has generally not been the case, at least with respect to a single jurisdiction. However, following the Sun Patent Trust v Vivo, and Ericsson v Transsion UPC actions, and in light of several supportive comments by some of the UPC judiciary [UPC rate setting article], it seems as if the UPC may join the list of jurisdictions willing to set FRAND rates.

Why multiple rate-setting actions may become more common

It has also mostly been the case that only one side of the dispute has requested a rate setting. Where multiple rate settings have been sought, as with Samsung v ZTE, it is because each side is prepared to have the FRAND rate determined by the court, but wishes to do so in a jurisdiction they perceive to be favourable to their case. With rate setting now well established in the UK and China, and with the increasing likelihood of rate setting becoming a strategic option at the UPC, there is certainly greater potential for parties to face multiple FRAND rate setting actions in a particular dispute. If so, what happens when different courts reach different conclusions as to what the FRAND rate should be?

What happens when courts reach different conclusions?

In the UK, a FRAND rate determination is not binding on an implementer. The implementer can refuse to enter into the court-determined licence; if so they will be deemed to be unwilling, having refused the offer of a FRAND licence, and, subject to a finding of patent infringement, will be subject to a patent injunction in the UK. It has been argued, in contrast, that a patent owner can be forced to offer and enter into a UK determined licence. This is because the UK treats FRAND disputes primarily as a matter of contract law, and it has been argued that a failure to offer a FRAND licence is a breach of contract which can be remedied by specific performance, i.e. issuing a positive injunction requiring the patent owner to enter the licence (or, as an alternative remedy by an award of damages). However, this has not yet been decided by the UK courts, and it is by no means certain that this will be the eventual outcome. Chinese FRAND determinations are potentially binding on the parties, but it is noted that in the case of ZTE v Samsung, the Chinese court enquired as to whether Samsung would abide by the Chongqing court’s decision, with Samsung responding that it always abides by the law, but it had given an undertaking to the UK court to abide by the UK court decision. Further, even if a court would be willing to force a party to enter into a FRAND licence, courts in other jurisdictions, notably Germany and the UPC, have been willing to issue anti-suit injunctions to prevent this, for example in the dispute between Amazon and Interdigital.

All of which means it is possible that multiple rate setting procedures could result in different determinations, with neither side able to actively enforce one on the other. Nevertheless, these independent adjudications have the potential to be important indications assisting the parties to reach settlement, which is what appears to have now happened in the Samsung and ZTE dispute. There was also some support for this from the UPC, which proposed that the parties enter into a global cross-licence on the basis of either the Chinese decision or the German ruling already handed down, but if not, suggested that they submit the case for mediation before the UPC’s Patent Mediation and Arbitration Centre (PMAC) (UPC_CFI_189/2025, Order of 13 May 2026, Settlement Proposal).

Could arbitration offer a practical alternative?

Clearly, conducting concurrent FRAND determinations in two or more jurisdictions raises concerns about efficiency. One possible alternative is the use of arbitration. This can arise with the agreement of the parties, and is sometimes useful in FRAND disputes, particularly in the case of renewals. As the parties have more control over both the procedure and the judicial panel, it has the potential to overcome some of the problems parties face in agreeing to a determination by a single court, although it does not entirely solve them. Lord Justice Arnold has even proposed that the UK court could set the terms of arbitration when parties were unable to agree this. The UK court has also ruled that a patentee can meet its FRAND obligation by offering an implementer a licence in which the final FRAND rate is determined by arbitration.

The direction of travel for FRAND disputes

Parties are bringing FRAND cases before an increasing number of courts around the world. Each has its own approach to the question of FRAND, and many seem unlikely to adopt a rate setting approach. Nevertheless, a number of recent judicial developments, including those in Samsung v ZTE, suggest that we may see more rate setting litigations, including concurrent rate setting actions, as well as rate setting by arbitration.

Need advice on FRAND and SEP disputes?

Our Litigation team advises on complex, cross-border patent and licensing disputes. Get in touch to discuss how we can support your strategy.

The Latest Thought Leadership pieces in the Content Hub

FRAND rate setting at the UPC: an emerging route for SEP owners?
November 10, 2026
The UPC could be emerging as an important new forum for FRAND rate setting. Drawing on recent patentee-led actions and judicial commentary, this article explores how SEP owners might seek a UPC determination of FRAND terms and what this developing approach could mean for European enforcement and licensing strategies.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
#
Consulting
​
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
#
Patenting
​
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
#
Patenting
​
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​